Development
DexCom, Inc.
DXCM
$82.26
$1.642.03%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 6.10% | 11.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.10% | 11.90% | |||
| Cost of Revenue | 7.45% | 8.25% | |||
| Gross Profit | 5.34% | 14.07% | |||
| SG&A Expenses | 8.47% | -4.24% | |||
| Depreciation & Amortization | -405.88% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.25% | 3.54% | |||
| Operating Income | 5.55% | 60.42% | |||
| Income Before Tax | 2.41% | 50.91% | |||
| Income Tax Expenses | -108.44% | 175.81% | |||
| Earnings from Continuing Operations | 112.34% | 4.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 112.34% | 4.14% | |||
| EBIT | 5.55% | 60.42% | |||
| EBITDA | 6.19% | 47.67% | |||
| EPS Basic | 113.74% | 4.17% | |||
| Normalized Basic EPS | 2.29% | 50.91% | |||
| EPS Diluted | 115.15% | 4.47% | |||
| Normalized Diluted EPS | 4.29% | 52.58% | |||
| Average Basic Shares Outstanding | -0.65% | -0.03% | |||
| Average Diluted Shares Outstanding | -2.55% | -1.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||